State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee

In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions....

Descripción completa

Detalles Bibliográficos
Autores: Ryan, Christine E., Ahn, Inhye E., Sekar, Aswin, Rawstron, Andrew, Almeida, Julia, Martin-Subero, Iñaki, Parry, Erin M., Alcoceba, Miguel, Calado, Dinis P., Orfao, Alberto, Langerak, Anton W., Veelken, Hendrik, Langerbeins, Petra, Stephens, Deborah M., Parikh, Sameer A., Niemann, Carsten U., Roulland, Sandrine, Stamatopoulos, Kostas, Slager, Susan L., Shanafelt, Tait, Ghia, Paolo, Okosun, Jessica, Davids, Matthew S.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:dnet:digitalcsic_::d86ea666a6688a1ea8c1d0bbe35052e9
Acceso en línea:http://hdl.handle.net/10261/426886
https://api.elsevier.com/content/abstract/scopus_id/105014752049
Access Level:acceso abierto
Palabra clave:B-cell lymphoma
Chronic lymphocytic leukaemia
Descripción
Sumario:In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.

Similares en LA Referencia